Cell Metab:补充缺失的肠道细菌菌株,或有助于治疗糖尿病

2017-10-23 唐一尘 科学网

荷兰的一项小规模临床试验发现,移植瘦人的粪便可以暂时提高肥胖男性的胰岛素耐受性——但只有一半受试者出现了反应。经过进一步调查,研究人员发现可以通过分析每个病人的粪便细菌组成,预测治疗的成败。这有助于为糖尿病患者的个性化粪便移植的发展提供帮助。相关论文近日刊登于《细胞—代谢》杂志。

荷兰的一项小规模临床试验发现,移植瘦人的粪便可以暂时提高肥胖男性的胰岛素耐受性——但只有一半受试者出现了反应。经过进一步调查,研究人员发现可以通过分析每个病人的粪便细菌组成,预测治疗的成败。这有助于为糖尿病患者的个性化粪便移植的发展提供帮助。相关论文近日刊登于《细胞—代谢》杂志。

“我们已经发现,可以根据粪便样本对人进行分类。”阿姆斯特丹大学的内科和血管医学部的Max Nieuwdorp说,“这让我们可以更敏感地分类疾病。”

在这一随机对照试验中,研究人员招募了38名患有代谢综合症的肥胖男性,其症状包括高血压、高血糖和多余脂肪。他们还招募了11位肠道菌群健康的瘦捐赠者。研究人员抽取了血样和粪便样本,并随机对肥胖男性和捐赠者进行随机配对。

实验显示,移植了粪便材料后,一半参与者出现了胰岛素敏感性的改善,而另一半则没有变化。研究人员比较了两组人在治疗前的肠道微生物样本,发现没有反应的人一开始肠道内的细菌多样性就较低。不过,这些只是短期的变化。3个月后,所有接受者的微生物菌群都回到了最初的状态。

“通过这项最新研究,我们能更深入了解肠道微生物群和人类新陈代谢之间的相互作用。”Nieuwdorp说。

这些结果还可以帮助研究人员预测粪移植的成功。如果接受者的粪便样本预先进行了筛选,那么治疗方法就会变得更加个性化。Nieuwdorp表示,“我们已经开始看到,通过补充缺失的肠道细菌菌株,或有助于治疗患者。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887745, encodeId=aa9a188e74555, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Aug 28 11:30:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896170, encodeId=7f1b18961e0fc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 03 01:30:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870237, encodeId=430618e0237f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 13 23:30:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960499, encodeId=5dde19604991f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 24 04:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369884, encodeId=29ec1369884d8, content=<a href='/topic/show?id=4f4081e22b0' target=_blank style='color:#2F92EE;'>#肠道细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81722, encryptionId=4f4081e22b0, topicName=肠道细菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Wed Oct 25 04:30:00 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2018-08-28 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887745, encodeId=aa9a188e74555, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Aug 28 11:30:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896170, encodeId=7f1b18961e0fc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 03 01:30:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870237, encodeId=430618e0237f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 13 23:30:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960499, encodeId=5dde19604991f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 24 04:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369884, encodeId=29ec1369884d8, content=<a href='/topic/show?id=4f4081e22b0' target=_blank style='color:#2F92EE;'>#肠道细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81722, encryptionId=4f4081e22b0, topicName=肠道细菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Wed Oct 25 04:30:00 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2018-01-03 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887745, encodeId=aa9a188e74555, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Aug 28 11:30:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896170, encodeId=7f1b18961e0fc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 03 01:30:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870237, encodeId=430618e0237f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 13 23:30:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960499, encodeId=5dde19604991f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 24 04:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369884, encodeId=29ec1369884d8, content=<a href='/topic/show?id=4f4081e22b0' target=_blank style='color:#2F92EE;'>#肠道细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81722, encryptionId=4f4081e22b0, topicName=肠道细菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Wed Oct 25 04:30:00 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887745, encodeId=aa9a188e74555, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Aug 28 11:30:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896170, encodeId=7f1b18961e0fc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 03 01:30:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870237, encodeId=430618e0237f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 13 23:30:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960499, encodeId=5dde19604991f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 24 04:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369884, encodeId=29ec1369884d8, content=<a href='/topic/show?id=4f4081e22b0' target=_blank style='color:#2F92EE;'>#肠道细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81722, encryptionId=4f4081e22b0, topicName=肠道细菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Wed Oct 25 04:30:00 CST 2017, time=2017-10-25, status=1, ipAttribution=)]
    2018-03-24 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887745, encodeId=aa9a188e74555, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Aug 28 11:30:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896170, encodeId=7f1b18961e0fc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 03 01:30:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870237, encodeId=430618e0237f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 13 23:30:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960499, encodeId=5dde19604991f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Mar 24 04:30:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369884, encodeId=29ec1369884d8, content=<a href='/topic/show?id=4f4081e22b0' target=_blank style='color:#2F92EE;'>#肠道细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81722, encryptionId=4f4081e22b0, topicName=肠道细菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Wed Oct 25 04:30:00 CST 2017, time=2017-10-25, status=1, ipAttribution=)]

相关资讯

JCI Insight:科学家发现:2型糖尿病血糖高低的关键,越胖反而血糖越低

耶鲁大学的一项最新研究表明,与瘦人相比,肥胖者和2型糖尿病患者的大脑中葡萄糖水平降低。研究人员说,这一发现可能会解释饮食行为紊乱,甚至可能导致肥胖和糖尿病患者患老年痴呆症的风险更高。

Diabetes:研究指出干扰胰岛β细胞增殖、导致糖尿病的罪魁祸首!

根据Diabetes发表的一项研究,研究人员已经发现通过抑制应激诱导的microRNA-708(miR-708),影响β细胞功能和葡萄糖调节的新机制。

盘点:近期关于二甲双胍研究一览

二甲双胍是单纯饮食控制及体育锻炼治疗无效的2型糖尿病首选用药,特别是肥胖的2型糖尿病。然而,二甲双胍是否有副作用,该如何吃才能发挥最大功效以及它又有什么其他作用呢?在此,小编整理了近期关于二甲双胍研究进展一览。【1】Metabolism:循环ApoJ与胰岛素抵抗密切相关!胰岛素抵抗是2型糖尿病的主要危险因素,载脂蛋白J(ApoJ)参与了心血管疾病和老年痴呆症等疾病的病理生理状态。然而,ApoJ

当心药物超敏反应综合征致暴发性1型糖尿病

患者女,68岁,主因“反复发热20d”就诊。

JAMA:比二甲双胍更有效果的药物将要出现

根据10月17日发表在《美国医学会杂志》(JournaloftheAmericanMedicalAssociation)上的临床证据显示,添加磺酰脲或二甲双胍治疗胰岛素与血红蛋白A1c(HbA1c)约减少1%有关,而添加磺酰脲类(但非二甲双胍)与更多的低血糖事件有关,效果更明显。

控糖治疗中,老饿咋办?

饥饿感是糖友在控糖治疗中经常遇到的一种反应。出现饥饿感时,首先应排除低血糖反应(属于相对性低血糖,血糖实际上在正常范围,并非真正的低血糖)。